Details

Autor(en) / Beteiligte

• Lassman, Andrew B
• Hoang-Xuan, Khê
• Polley, Mei-Yin C
• Brandes, Alba A
• Cairncross, J Gregory
• Kros, Johan M
• Ashby, Lynn S
• Taphoorn, Martin J B
• Souhami, Luis
• Dinjens, Winand N M
• Laack, Nadia N
• Kouwenhoven, Mathilde C M
• Fink, Karen L
• French, Pim J
• Macdonald, David R
• Lacombe, Denis
• Won, Minhee
• Gorlia, Thierry
• Mehta, Minesh P
• van den Bent, Martin J

Titel

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

Ist Teil von

• Journal of clinical oncology, 2022-08, Vol.40 (23), p.2539-2545

Ort / Verlag

United States: Wolters Kluwer Health

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• JCO Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.